Sign up for our Oncology Central weekly news round-up

Pemigatinib receives positive CHMP opinion for the treatment of cholangiocarcinoma

Written by Rachel Jenkins, Future Science Group

pemigatinib

Incyte (DE, USA) recently announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the conditional marketing authorization of pemigatinib for the treatment of adults with unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that is relapsed or refractory, after at least one line of systemic therapy. The opinion is based on data from the FIGHT-202 study evaluating the safety and efficacy of pemigatinib. The CHMP’s opinion is now being reviewed by the European Commission, which has the authority to...

To view this content, please register now for access

It's completely free